Companies › Arialys Australia
1 active drug program in 1 registered trial: 1 Phase 2; Psychiatry; next expected readout Nov 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ART5803 Monovalent antibody that binds to the NTD of NMDAR NR1 subunit and blocks pathogenic anti- | GRIN1 | Phase 2 | Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE) | Nov 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07093333 | ART5803 | Phase 2 | Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE) | Psychiatry | Nov 2027 |
Syndeio Biosciences GRIN Therapeutics SHINKEI Therapeutics Aptinyx Johnson & Johnson (Janssen) atai Therapeutics
atai Therapeutics SyneuRx International (Taiwan) Syndeio Biosciences NeuroRx Bazelet Nehushtan
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.